These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436 [TBL] [Abstract][Full Text] [Related]
3. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766 [TBL] [Abstract][Full Text] [Related]
17. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Goffin J; Baral S; Tu D; Nomikos D; Seymour L Clin Cancer Res; 2005 Aug; 11(16):5928-34. PubMed ID: 16115935 [TBL] [Abstract][Full Text] [Related]
18. Vaccination with Theratope (STn-KLH) as treatment for breast cancer. Holmberg LA; Sandmaier BM Expert Rev Vaccines; 2004 Dec; 3(6):655-63. PubMed ID: 15606349 [TBL] [Abstract][Full Text] [Related]